These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26783962)

  • 1. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
    Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
    J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
    Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E; Choi YL; Ahn MJ; Han J
    Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.